Market Context — Why This Technology, Why Now

The global healthcare industry is undergoing a transformative shift towards personalized medicine and non-invasive diagnostics, demanding advanced biomaterials for precise in-vivo applications. Regulatory bodies increasingly emphasize the safety and long-term stability of agents used in the human body, pushing for innovations that minimize toxicity and maximize diagnostic accuracy. This creates intense competitive pressure for pharmaceutical and medical device companies to adopt next-generation labeling and delivery systems that offer superior performance and patient safety.

Key Competitive Advantages
01

Enhances Biocompatibility and Environmental Stability: Coating gold nanorods with silica ensures in-vivo safety and significantly improves stability against temperature and pH changes.

02

Sustains Fluorescence Intensity Long-Term: Chemically binding labeling substances via a spacer suppresses self-quenching, maintaining stable fluorescence intensity at practical levels.

03

Simplifies Manufacturing and Offers Labeling Versatility: Specific manufacturing steps allow easy binding of diverse labeling substances, achieving high versatility for various diagnostic and therapeutic applications.

Market Opportunity
Early Disease Diagnostics
$10B–$15B globally (AI est.)
In fields like cancer and neurodegenerative diseases, where early detection significantly impacts treatment outcomes, there is growing demand for highly sensitive bioimaging enabled by this technology.
Major diagnostic kit manufacturers Medical imaging device developers Biotech firms specializing in oncology/neurology
Targeted Drug Delivery
$5B–$10B globally (AI est.)
The pharmaceutical industry prioritizes delivering drugs directly to affected areas to reduce systemic side effects and maximize therapeutic efficacy, making this technology promising for nanocarrier applications.
Pharmaceutical companies developing novel therapeutics Specialty drug delivery system developers Biopharmaceutical R&D divisions
Bioimaging Research
$2.5B–$3.5B globally (AI est.)
Highly stable and low-toxicity fluorescent probes are essential for elucidating detailed biological phenomena at cellular and tissue levels, indicating expanding use in basic research.
Life science research tool providers Academic research institutions Contract research organizations (CROs)
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent establishes robust protection for the structure of labeled silica-coated gold nanorods and their manufacturing method, covering multiple aspects of the technology. It successfully navigated a rigorous examination process, demonstrating strong claim strength and low invalidation risk, thereby offering a clear competitive advantage to licensees.

Competitive White Space

This patent focuses on the nanorod structure and synthesis. Licensees could develop novel detection assays, specific disease biomarkers, or integrate these nanorods into advanced microfluidic diagnostic devices to build complementary IP.

Economic Impact
~$1.0M/year estimated diagnostic development cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Improved probe stability in novel biomedical diagnostic development could reduce development time by 20%. For a project with an average 5-year development period and annual development costs of ~$3.5M (AI est.), this could yield an annual reduction of ~$0.5M (AI est.). Additionally, an estimated ~$0.5M (AI est.) in annual savings is expected from reduced quality control costs and improved yield in the manufacturing process, totaling an estimated annual economic impact of ~$1.0M (AI est.).

Speed to Market
3× faster than in-house development
This technology's specific structure and manufacturing method for silica-coated gold nanorods with chemically bound labeling substances are already patented. This eliminates the need for licensees to conduct R&D from scratch, significantly shortening development time by combining it with existing nanomaterial synthesis and labeling technologies. With the core technology principles established, rapid market entry from the demonstration phase is anticipated.
Competitive Positioning

X: Diagnostic Accuracy & Stability
Y: Biocompatibility & Manufacturing Efficiency

Business Models & Applications
🧪 Licensing to Diagnostic Manufacturers
Offer implementation licenses to existing diagnostic manufacturers for the development, production, and sale of new high-sensitivity diagnostic agents based on this technology.
🤝 Collaborative R&D with Pharmaceutical Companies
Aim to create innovative therapeutic drugs through joint research and development of targeted drug delivery systems for specific diseases.
🔬 Probe Provision for Research Institutions
Provide manufacturing and sales services for customized labeled nanorod probes to universities and research institutions, supporting their research and development efforts.
Adjacent Application Opportunities
🏥 Medical Devices
Labels for Implantable Biosensors
Leveraging its biocompatibility and stability, this technology could enhance the long-term monitoring accuracy of implantable biosensors by applying it to their detection surfaces, potentially extending sensor lifespan by 2x.
🔬 Environmental Monitoring
High-Sensitivity Detection of Pollutants
Utilizing its environmental stability and labeling versatility, this technology could be adapted for high-sensitivity, real-time environmental monitoring systems by binding labels that react to specific pollutants, detecting concentrations 10x lower than current methods.
🍎 Food Safety
Rapid Pathogen & Allergen Detection
Applying its ease of manufacturing and sustained fluorescence, this technology could contribute to developing rapid and highly accurate test kits for detecting pathogens and allergens in food, reducing detection time by up to 50%.
Integration Roadmap — Estimated 27-Month Deployment
Phase 1: Basic Validation & Optimization
Duration: 4 months
Select target labeling substances for the licensee and optimize binding conditions for this technology, followed by basic in vitro performance evaluation.
Phase 2: Prototype Development & Evaluation
Duration: 9 months
Develop prototype labeled nanorods using the selected labeling substances and proceed with in vitro and cellular-level efficacy and safety evaluations.
Phase 3: Preclinical & Mass Production Preparation
Duration: 14 months
Plan and conduct preclinical trials using animal models, and establish manufacturing process scale-up and quality control systems for future mass production.
Technical Feasibility
This technology defines a clear structure and manufacturing steps for silica-coated gold nanorods with chemically bound labeling substances in its patent claims. This modular structure has high compatibility with existing nanomaterial synthesis lines and bioconjugation technologies, potentially allowing licensees to integrate it into existing production processes with relatively low capital investment. The low technical barrier is expected to enable rapid adoption.
Success Scenario
If licensees utilize this technology, it could enable highly sensitive, non-invasive identification of early-stage diseases that were previously difficult to detect. This is estimated to shorten diagnostic time by 1/3 and improve treatment success rates by 15%, significantly enhancing patient quality of life. In drug development, it could enable efficient targeted drug delivery to specific cells, potentially shortening new drug development periods and increasing success probabilities.
Patent Record
APPLICATION NO.
特願2020-209844
REGISTRATION NO.
7607312
FILING DATE
2020/12/18
GRANT DATE
2024/12/19
EXPIRATION DATE
2040/12/18
PATENT HOLDER
国立大学法人山梨大学
Examination History
2021年01月12日
手続補正書（自発・内容）
2023年12月12日
出願審査請求書
2024年06月28日
拒絶理由通知書
2024年08月27日
意見書
2024年08月27日
手続補正書（自発・内容）
2024年11月28日
特許査定